18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer
patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study
participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell
carcinoma (RCC) who are receiving antiangiogenesis treatment.